These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11157921)

  • 21. Variable daptomycin susceptibility in patients receiving intravenous vancomycin for meticillin-resistant Staphylococcus aureus infections.
    Golden M; Shaib W; Havill N
    Int J Antimicrob Agents; 2010 Mar; 35(3):306-8. PubMed ID: 20036108
    [No Abstract]   [Full Text] [Related]  

  • 22. Impact of vancomycin minimum inhibitory concentration on mortality among critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.
    Woods CJ; Chowdhury A; Patel VM; Shorr AF
    Infect Control Hosp Epidemiol; 2012 Dec; 33(12):1246-9. PubMed ID: 23143364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An infant with an MRSA ventriculo-gallbladder shunt infection.
    Weiner GM; Bui CJ; Steele RW
    Clin Pediatr (Phila); 2011 Mar; 50(3):269-71. PubMed ID: 21307082
    [No Abstract]   [Full Text] [Related]  

  • 24. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin.
    Price J; Atkinson S; Llewelyn M; Paul J
    Clin Infect Dis; 2009 Apr; 48(7):997-8. PubMed ID: 19260820
    [No Abstract]   [Full Text] [Related]  

  • 25. Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?
    Patel K; Crumby AS; Maples HD
    Paediatr Drugs; 2015 Apr; 17(2):97-103. PubMed ID: 25644329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increasing levels of minimum inhibitory concentration vancomycin in methicillin resistant Staphylococcus aureus alarming bell for vancomycin abusers?
    Veer P; Chande C; Chavan S; Wabale V; Chopdekar K; Bade J; Joshi A
    Indian J Med Microbiol; 2010; 28(4):413-4. PubMed ID: 20966589
    [No Abstract]   [Full Text] [Related]  

  • 27. Vancomycin-intermediate Staphylococcus epidermidis: curio or omen?
    Strausbaugh LJ
    Infect Control Hosp Epidemiol; 1999 Mar; 20(3):163-5. PubMed ID: 10100540
    [No Abstract]   [Full Text] [Related]  

  • 28. AUC-Based Monitoring of Vancomycin: Closing the Therapeutic Window.
    Biagi MJ; Butler DA; Wenzler E
    J Appl Lab Med; 2019 Jan; 3(4):743-746. PubMed ID: 31639746
    [No Abstract]   [Full Text] [Related]  

  • 29. Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone.
    Albayati ZA; Sunkara M; Schmidt-Malan SM; Karau MJ; Morris AJ; Steckelberg JM; Patel R; Breen PJ; Smeltzer MS; Taylor KG; Merten KE; Pierce WM; Crooks PA
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1865-8. PubMed ID: 26666918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Use of glycopeptides in the treatment of infections caused by methicillin-resistant staphylococci].
    Bouza E; Rodríguez-Créixems M; Muñoz P
    Rev Clin Esp; 1997 Sep; 197 Suppl 2():52-8. PubMed ID: 9441324
    [No Abstract]   [Full Text] [Related]  

  • 31. Failure of once-daily vancomycin for staphylococcal endocarditis.
    Marik PE
    Pharmacotherapy; 1998; 18(3):650-2. PubMed ID: 9620118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections-a systematic review and meta-analysis.
    Diaz R; Afreixo V; Ramalheira E; Rodrigues C; Gago B
    Clin Microbiol Infect; 2018 Feb; 24(2):97-104. PubMed ID: 28648858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intrathecal administration of vancomycin for coagulase-negative staphylococcal meningitis in a patient with blunt head injury: case report.
    Kawamoto H; Inagawa T; Ikawa F; Sakamoto S; Urabe S
    J Trauma; 2002 Nov; 53(5):1010-2. PubMed ID: 12435961
    [No Abstract]   [Full Text] [Related]  

  • 34. Firvanq--vancomycin oral solution.
    Med Lett Drugs Ther; 2018 Jul; 60(1551):122. PubMed ID: 30036349
    [No Abstract]   [Full Text] [Related]  

  • 35. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.
    Mariani PG; Sader HS; Jones RN
    J Antimicrob Chemother; 2006 Aug; 58(2):481-3. PubMed ID: 16847029
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of severe infections caused by Staphylococcus aureus: a change in the vancomycin paradigm?
    Aranha Camargo LF
    Shock; 2008 Oct; 30 Suppl 1():67-9. PubMed ID: 18704006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial dosing of vancomycin in critically ill patients.
    Kees MG; Vögeler S; Hilpert JW
    Int J Antimicrob Agents; 2011 Jul; 38(1):91-2. PubMed ID: 21546217
    [No Abstract]   [Full Text] [Related]  

  • 38. Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies.
    Dunne MW; Sahm D; Puttagunta S
    Ann Clin Microbiol Antimicrob; 2015 Apr; 14():19. PubMed ID: 25885674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia.
    Jacobson LM; Milstone AM; Zenilman J; Carroll KC; Arav-Boger R
    Pediatr Infect Dis J; 2009 May; 28(5):445-7. PubMed ID: 19295462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
    Adane ED; Herald M; Koura F
    Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.